Get the Stockscreener App
915.30
0.50%
-4.64
After Hours:
915.30
Argen X Se Adr stock is traded at $915.30, with a volume of 243.70K.
It is down -0.50% in the last 24 hours and up +3.73% over the past month.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
See More
Previous Close:
$919.94
Open:
$914.15
24h Volume:
243.70K
Relative Volume:
0.72
Market Cap:
$56.92B
Revenue:
$4.16B
Net Income/Loss:
$1.29B
P/E Ratio:
46.74
EPS:
19.5837
Net Cash Flow:
$734.26M
1W Performance:
+0.64%
1M Performance:
+3.73%
6M Performance:
+15.05%
1Y Performance:
+69.93%
1-Day Range:
$906.23
$920.30
1-Week Range:
$906.23
$953.58
52-Week Range:
$538.91
$953.58
Argen X Se Adr Stock (ARGX) Company Profile
Compare ARGX vs VRTX, REGN, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
915.30 | 57.21B | 4.16B | 1.29B | 734.26M | 19.58 |
VRTX
Vertex Pharmaceuticals Inc
|
498.43 | 132.55B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
662.88 | 70.90B | 14.92B | 4.42B | 3.79B | 41.04 |
ALNY
Alnylam Pharmaceuticals Inc
|
323.50 | 42.94B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.77 | 40.49B | 742.00K | -1.37B | -1.07B | -7.0731 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Dec-18-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-24-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-15-25 | Resumed | Truist | Buy |
| Sep-11-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-08-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| May-13-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-17-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-12-25 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-17-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Nov-12-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-05-24 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Nov-01-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Strong Buy |
| Oct-04-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-06-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jul-25-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-20-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-31-23 | Initiated | Scotiabank | Sector Perform |
| Jul-24-23 | Downgrade | UBS | Buy → Neutral |
| Jul-17-23 | Resumed | Evercore ISI | Outperform |
| Jun-15-23 | Initiated | Societe Generale | Sell |
| May-31-23 | Initiated | UBS | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-14-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-07-22 | Initiated | William Blair | Outperform |
| Oct-12-22 | Initiated | Oppenheimer | Perform |
| Jul-29-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-22 | Resumed | Stifel | Buy |
| May-03-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-29-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Sep-23-21 | Upgrade | Redburn | Neutral → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-23-21 | Initiated | Deutsche Bank | Hold |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jun-18-21 | Initiated | UBS | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-23-21 | Initiated | Redburn | Neutral |
| Mar-05-21 | Reiterated | H.C. Wainwright | Neutral |
| Feb-02-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-04-21 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-20 | Initiated | H.C. Wainwright | Neutral |
| Feb-10-20 | Initiated | BofA/Merrill | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Oct-31-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-22-19 | Initiated | JP Morgan | Overweight |
| Sep-27-19 | Initiated | Wells Fargo | Market Perform |
| Sep-16-19 | Resumed | Cowen | Outperform |
| Jun-28-19 | Initiated | Robert W. Baird | Outperform |
| Jan-18-19 | Resumed | SunTrust | Buy |
| Jan-04-19 | Initiated | Morgan Stanley | Overweight |
| Dec-17-18 | Initiated | Goldman | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Jun-29-18 | Initiated | Nomura | Buy |
| Apr-09-18 | Initiated | SunTrust | Buy |
| Jan-29-18 | Reiterated | JMP Securities | Mkt Outperform |
View All
Argen X Se Adr Stock (ARGX) Latest News
VCRE|Vicore Pharma Holding AB ADR|Price:14.124|Chg%:-0.901 - TradingKey
RBC Capital Adjusts argenx SE ADR Price Target to $945 From $890, Maintains Outperform Rating - marketscreener.com
Planet Labs Upgraded, Royal Caribbean Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
This Profitable Autoimmune Biotech Trades Near A High And A Buy Point - Investor's Business Daily
Argenx, stock of the day, eyes buy point amid triple-digit growth - MSN
Argenx Fends Off First-Quarter Seasonality, But Shares Defy Analysts' Bullish Views - Investor's Business Daily
Argenx stock holds the focus on its global immunology franchise. - AD HOC NEWS
ARGXArgen X SE ADR Options - Finviz
Argenx beats profit forecasts despite revenue miss - Investing.com
Argenx stock hits all-time high at 934.69 USD - Investing.com
ARGX Stock Price, Quote & Chart - ChartMill
BofA raises argenx stock price target to $1,088 on myositis data - Investing.com
Argenx, Stock Of The Day, Eyes Buy Point Amid Triple-Digit Growth - Investor's Business Daily
A2H9WD Forecast — Price Target — Prediction for 2027 - TradingView
European ADRs Climb In Thursday U.S. Morning Session: ARGX, PHIA, CRTO In Focus - foreignpolicyjournal.com
argenx SE Sponsored ADR Actuals & Estimates (NASDAQ:ARGX) - TradingView
H.C. Wainwright reiterates argenx stock rating on myositis trial update By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates argenx stock rating on myositis trial update - Investing.com
Okta To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Wednesday - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Can Argenx Retake Its Record High — And A Buy Point — On A New Vyvgart Strategy? - Investor's Business Daily
TD Cowen reiterates Buy on argenx stock, cites IMNM opportunity By Investing.com - Investing.com South Africa
TD Cowen reiterates Buy on argenx stock, cites IMNM opportunity - Investing.com
RBC Capital reiterates argenx stock Outperform on myositis data - Investing.com
RBC Capital reiterates argenx stock Outperform on myositis data By Investing.com - Investing.com Australia
Argenx stock price target held at $1,014 by Oppenheimer on myositis strategy - Investing.com Nigeria
Argenx stock falls after myositis drug trial update - Investing.com
Biotech breakout: iShares Biotechnology ETF hits all-time high - MSN
Form 6K argenx NV ADR For: 23 June - Investing.com UK
Form 6K argenx NV ADR For: 23 June By Investing.com - Investing.com Nigeria
argenx to Host Autoimmune Myositis R&D Webinar - GlobeNewswire Inc.
Novabridge Biosciences ADR (NBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Galapagos ADR Representing Ord Shs (LKFT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Argenx SE Stock (NL0010832176): Analyst price target move puts biotech in focus - AD HOC NEWS
European ADRs Rose In US Trading As Biotech Led - Finimize
European Equities Traded in US as ADRs Rise in Thursday Trading - Moomoo
Sanofi Scraps Its Argenx Rival; Why Another Biotech Took The Hit - Investor's Business Daily
ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know - TradingView
Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock? - Yahoo Finance
William O'Neil Initiates Argenx at Buy - Moomoo
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference - Barchart.com
H.C. Wainwright reiterates Buy on argenx stock, $940 target - Investing.com UK
H.C. Wainwright reiterates Buy on argenx stock, $940 target By Investing.com - Investing.com South Africa
Form 6K argenx NV ADR For: 3 June By Investing.com - Investing.com India
Argen X Se Adr Stock (ARGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):